NCT00540644

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Attaya Suvannasankha · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.

Detailed description

This is a phase II single institution trial in patients with newly diagnosed multiple myeloma. Revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. Cyclophosphamide 50 mg p.o. BID daily on days 1-21 of each 28-day cycle. Prednisone 50 mg p.o. Q.O.D..

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	lenalidomide (Revlimid®)	25 mg p.o. daily on days 1-21 of each 28 day cycle
DRUG	Cyclophosphamide	50 mg p.o. BID daily on days 1-21 of each 28 day cycle
DRUG	Prednisone	50 mg p.o. Q.O.D.

Timeline

• Start date: 2007-10-01
• Primary completion: 2012-12-01
• Completion: 2014-08-01
• First posted: 2007-10-08
• Last updated: 2016-06-21
• Results posted: 2016-06-21

Locations

1 site across 1 country: United States